Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study

PLoS Medicine

Volumn 10, Issue 6, 2013, Pages

  Pichler, Irene ^a   Del Greco, M Fabiola ^a   Gögele, Martin ^a   Lill, Christina M ^b,c   Bertram, Lars ^b   Do, Chuong B ^d   Eriksson, Nicholas ^d   Foroud, Tatiana ^e   Myers, Richard H ^f   Nalls, Michael ^g   Keller, Margaux F ^g,h   Benyamin, Beben ^i,j   Whitfield, John B ⁱ   Pramstaller, Peter P ^a,k,l   Hicks, Andrew A ^a   Thompson, John R ^m   Minelli, Cosetta ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d 23andMe Inc ^*  (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h TEMPLE UNIVERSITY   (United States)

ⁱ QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k General Central Hospital   (Italy)

^l UNIVERSITY OF LÜBECK   (Germany)

^m UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN;

ALLELE; ARTICLE; DNA POLYMORPHISM; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEREDITY; HUMAN; IRON BLOOD LEVEL; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; PARKINSON DISEASE; PLEIOTROPY; RISK; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRON; MENDELIAN RANDOMIZATION ANALYSIS; PARKINSON DISEASE; RISK FACTORS;

EID: 84879529900     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001462     Document Type: Article

References (68)

1. Crichton RR, Dexter DT, Ward RJ, (2011) Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm 118: 301-314.
2. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR, (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873.
3. Dusek P, Jankovic J, Le W, (2012) Iron dysregulation in movement disorders. Neurobiol Dis 46: 1-18.
4. Forno LS, (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
6. Mariani S, Ventriglia M, Simonelli I, Donno S, Bucossi S, et al. (2013) Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol Aging 34: 632-633.
7. Davey Smith G, Ebrahim S, (2005) What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 330: 1076-1079.
8. Davey Smith G, Ebrahim S, (2003) 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22.
9. Pierce BL, Ahsan H, Vanderweele TJ, (2011) Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40: 740-752.
10. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, et al. (2012) Using multiple genetic variants as instrumental variables for modifiable risk factors. Stats Methods Med Res 21: 223-242.
11. Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, et al. (2009) Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 41: 1173-1175.
12. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, et al. (2012) Comprehensive research synopsis and systematic meta-analyses in parkinson's disease genetics: The PDGene database. PLoS Genet 8: e1002548 doi:10.1371/journal.pgen.1002548.
13. Greco V, De Marco EV, Rocca FE, Annesi F, Civitelli D, et al. (2011) Association study between four polymorphisms in the HFE, TF and TFR genes and Parkinson's disease in southern Italy. Neurol Sci 32: 525-527.
14. Halling J, Petersen MS, Grandjean P, Weihe P, Brosen K, (2008) Genetic predisposition to parkinson's disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenet Genomics 18: 209-212.
15. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, et al. (2006) Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a portuguese cohort. BMC Neurol 6: 24.
16. Dekker MC, Giesbergen PC, Njajou OT, van Swieten JC, Hofman A, et al. (2003) Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett 348: 117-119.
17. Borie C, Gasparini F, Verpillat P, Bonnet AM, Agid Y, et al. (2002) Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 249: 801-804.
18. Buchanan DD, Silburn PA, Chalk JB, Le Couteur DG, Mellick GD, (2002) The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci Lett 327: 91-94.
19. Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, White LR, et al. (2007) Prevalence of haemochromatosis gene mutations in Parkinson's disease. J Neurol, Neurosurg Psychiatry 78: 315-317.
20. Biasiotto G, Goldwurm S, Finazzi D, Tunesi S, Zecchinelli A, et al. (2008) HFE gene mutations in a population of Italian Parkinson's disease patients. Parkinsonism Relat Disord 14: 426-430.
21. Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, et al. (2006) Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett 407: 16-19.
22. Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, et al. (2012) Meta-analysis of Parkinson's disease: Identification of a novel locus, RIT2. Ann Neurol 71: 370-384.
23. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 7: e1002141 doi:10.1371/journal.pgen.1002141.
24. International Parkinson Disease Genomics Consortium (2011) Nalls MA, Plagnol V, Hernandez DG, Sharma M, et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377: 641-649.
25. International Parkinson's Disease Genomics Consortium (IPDGC), Wellcome Trust Case Control Consortium 2 (WTCCC2) (2011) A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 7: e1002142 doi:10.1371/journal.pgen.1002142.
26. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593-605.
27. Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, et al. (2006) Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 5: 911-916.
28. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
29. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, et al. (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74: 97-109.
30. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781-785.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
32. D Didelez V, Meng S, (2010) Assumptions of IV methods for observational epidemiology. Stat Sci 25: 22-40.
33. Bautista LE, Smeeth L, Hingorani AD, Casas JP, (2006) Estimation of bias in nongenetic observational studies using "mendelian triangulation". Ann Epidemiol 16: 675-680.
34. Thomas DC, Lawlor DA, Thompson JR, (2007) Re: Estimation of bias in nongenetic observational studies using "mendelian triangulation" by Bautista et al. Ann Epidemiol 17: 511-513.
35. Pierce BL, Ahsan H, Vanderweele TJ, (2011) Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40: 740-752.
36. Tanner CM, Goldman SM, (1996) Epidemiology of Parkinson's disease. Neurol Clin 14: 317-335.
37. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, et al. (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64: 990-997.
38. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ, (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52: 276-284.
39. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, et al. (1999) In vitro and in vivo studies investigating possible antioxidant actions of nicotine: Relevance to Parkinson's and Alzheimer's diseases. Biochim Biophy Acta 1454: 143-152.
40. Morck TA, Lynch SR, Cook JD, (1983) Inhibition of food iron absorption by coffee. Am J Clin Nutr 37: 416-420.
41. Zijp IM, Korver O, Tijburg LB, (2000) Effect of tea and other dietary factors on iron absorption. Crit Rev Food Sci Nutr 40: 371-398.
42. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O, (2012) Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 133: 267-274.
43. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, et al. (2002) Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59: 999-1005.
44. Walter U, Witt R, Wolters A, Wittstock M, Benecke R, (2012) Substantia nigra echogenicity in Parkinson's disease: Relation to serum iron and C-reactive protein. J Neural Transm 119: 53-57.
45. Logroscino G, Chen H, Wing A, Ascherio A, (2006) Blood donations, iron stores, and risk of Parkinson's disease. Mov Disord 21: 835-838.
46. Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, et al. (2009) Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology 73: 1381-1387.
47. Levenson CW, Cutler RG, Ladenheim B, Cadet JL, Hare J, et al. (2004) Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp Neurol 190: 506-514.
48. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, et al. (2011) Dietary intake of metals and risk of Parkinson's disease: a case-control study in Japan. J Neurol Sci 306: 98-102.
49. Ramsey AJ, Hillas PJ, Fitzpatrick PF, (1996) Characterization of the active site iron in tyrosine hydroxylase. Redox states of the iron. J Biol Chem 271: 24395-24400.
50. Beard J, Erikson KM, Jones BC, (2003) Neonatal iron deficiency results in irreversible changes in dopamine function in rats. J Nutr 133: 1174-1179.
51. Levenson CW, Tassabehji NM, (2004) Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res Rev 3: 251-263.
52. Rhodes SL, Ritz B, (2008) Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis 32: 183-195.
53. Castiglioni E, Finazzi D, Goldwurm S, Pezzoli G, Forni G, et al. (2010) Analysis of nucleotide variations in genes of iron management in patients of Parkinson's disease and other movement disorders. Parkinsons Dis 2011: 827693.
54. Castiglioni E, Finazzi D, Goldwurm S, Levi S, Pezzoli G, et al. (2010) Sequence variations in mitochondrial ferritin: Distribution in healthy controls and different types of patients. Genet Test Mol Biomarkers 14: 793-796.
55. Ezquerra M, Campdelacreu J, Munoz E, Tolosa E, (2005) Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. J Neurol 252: 1269-1270.
56. He Q, Du T, Yu X, Xie A, Song N, et al. (2011) DMT1 polymorphism and risk of Parkinson's disease. Neurosci Lett 501: 128-131.
57. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. (2003) The discovery of the new haemochromatosis gene. 1996. J Hepatol 38: 704-709.
58. Du X, She E, Gelbart T, Truksa J, Lee P, et al. (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320: 1088-1092.
59. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399-408.
60. Bradley LA, Johnson DD, Palomaki GE, Haddow JE, Robertson NH, et a, (1998) Hereditary haemochromatosis mutation frequencies in the general population. J Med Screen 5: 34-36.
61. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, et al. (1997) Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 94: 12384-12389.
62. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, et al. (1997) The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272: 14025-14028.
63. Lebrón JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, et al. (1998) Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93: 111-123.
64. An P, Wu Q, Wang H, Guan Y, Mu M, et al. (2012) TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia. Hum Mol Genet 21: 2124-2131.
65. Nai A, Pagani A, Silvestri L, Campostrini N, Corbella M, et al. (2011) TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 118: 4459-4462.
66. Fleiss JL, (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2: 121-145.
67. Tamura T, Goldenberg RL, Hou J, Johnston KE, Cliver SP, Ramey SL, et al. (2002) Cord serum ferritin concentrations and mental and psychomotor development of children at five years of age. J Ped 186: 458-463.
68. Harbord RM, Didelez V, Palmer TM, Meng S, Sterne JA, et al. (2013) Severity of bias of a simple estimator of the causal odds ratio in mendelian randomization studies. Stat Med 32: 1246-1258.